Jump to content

Francisco J. Blanco: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
expand from better source
No edit summary
Tag: Reverted
Line 1: Line 1:
{{Short description|Spanish chemist}}
{{Use dmy dates|cs1-dates=ly|date=December 2023}}
{{Use list-defined references|date=December 2023}}
{{Family name hatnote|lang=Spanish|[[Blanco (surname)|Blanco]]|[[Gutiérrez]]}}
'''Francisco José Blanco Gutiérrez''' is a Spanish chemist whose research applies [[nuclear magnetic resonance]] to [[structural biology]]. He works at the Center for Biological Research of the Spanish National Research Council (CIB-CSIC), in Madrid, Spain, where he leads the Biomolecular NMR group.<ref name=csic>{{citation|url=https://www.cib.csic.es/research/structural-and-chemical-biology/biomolecular-nmr|title=Biomolecular NMR|publisher=Center for Biological Research|access-date=2023-12-27}}</ref>


Francisco Javier Blanco García,(Cee, A Coruña, 1963) is a Spanish-born medical professional, has established a notable career in the field of [[Rheumatology]].<ref>{{Cite web |title=pdi.udc.es |url=https://pdi.udc.es/en/File/Pdi/PM7GH}}</ref> He is a Full Professor of Rheumatology at the [[University of A Coruña]], Head of the Clinical and Translational Rheumatology Section at the A Coruña University Hospital, Coordinator of the Rheumatology-Health Research Group (GIR) at INIBIC and CICA-UDC, and Scientific Director of “Catedra UDC-FSR”.
Blanco has a 1992 Ph.D. from the [[Complutense University of Madrid]]. As a doctoral student he worked for the Institute of the Structure of Matter of the Spanish National Research Council (IEM-CSIC). He was a postdoctoral researcher at the [[European Molecular Biology Laboratory]]. From 2000 to 2002 he worked for CSIC again, before taking a position at the Spanish National Cancer Research Center (CNIO). He became IKERBASQUE Research Professor at the Center for Cooperative Research in Biosciences (CIC bioGUNE) in 2007, and took his present position at CIB-CSIC in 2020. He also holds an honorary professorship at the [[Autonomous University of Madrid]].<ref name=csic/>

==Education==

Francisco Javier Blanco García began his higher education at the [[Universidad de Santiago de Compostela]], Spain, where he graduated with a Bachelor of Science degree in Medicine and Surgery in 1987, excelling as the First of Class. Blanco's postgraduate journey included a residency in Rheumatology at the Hospital Universitario 12 Octubre in Madrid, completed in 1992, and a Research Fellowship in Medicine at the [[University of California, San Diego]], Martin Lot’s Lab in 1993-94. He achieved his PhD in Medicine from the Universidad de A Coruña, Spain, in 1998.<ref>{{Cite web |title=Ilmo. Sr. D. Francisco Javier Blanco García - Real Academia Nacional de Medicina |url=https://www.ranm.es/academicos/academicos-correspondientes/nacionales/4803-ilmo-sr-d-francisco-javier-blanco-garcia.html |access-date=2024-04-14 |website=www.ranm.es}}</ref><ref>{{Cite web |title=Dr. Francisco J. Blanco García |url=https://www.elsuplemento.es/premiado/dr.-francisco-j.-blanco-garcia |access-date=2024-04-14 |website=www.elsuplemento.es |language=es}}</ref>

==Research==
Prof. Francisco Javier Blanco García's research career is marked by pioneering contributions in [[rheumatology]], particularly in understanding [[osteoarthritis]].<ref>{{Cite web |last=jfersan2 |title=Reumatología |url=http://www.inibic.es/portfolio-items/reumatologia/ |access-date=2024-04-14 |website=INIBIC |language=es}}</ref> He was the first to identify [[apoptosis]] in human joint [[chondrocytes]], linking it to cartilage destruction in osteoarthritis and associating it with [[nitric oxide]] synthesis.<ref>{{Cite journal |last=de Andrés |first=María C. |last2=Maneiro |first2=Emilia |last3=Martín |first3=Miguel A. |last4=Arenas |first4=Joaquín |last5=Blanco |first5=Francisco J. |date=2013-09-11 |title=Nitric oxide compounds have different effects profiles on human articular chondrocyte metabolism |url=https://doi.org/10.1186/ar4295 |journal=Arthritis Research & Therapy |volume=15 |issue=5 |pages=R115 |doi=10.1186/ar4295 |issn=1478-6354 |pmc=PMC3978712 |pmid=24025112}}</ref> This revelation shifted the understanding of osteoarthritic cartilage destruction, previously attributed to [[necrosis]].<ref>{{Cite thesis |title=Implicación del factor de necrosis tumoral-alfa (TNF-alfa) y de interleuquina 1 (IL-1) en la disfunción mitocondrial del condrocito humano: estudio en el proceso apoptótico |url=https://dialnet.unirioja.es/servlet/tesis?codigo=45981 |publisher=Universidade da Coruña |date=2005 |degree=http://purl.org/dc/dcmitype/Text |language=es |first=Beatriz |last=Caramés}}</ref> Blanco is also a leader in studying mitochondria's role in osteoarthritis, notably in mitochondrial genetics as [[biomarkers]] for knee osteoarthritis.<ref>{{Cite web |title=cica.udc.gal |url=https://cica.udc.gal/research_project/novel-prediction-model-for-pain-progression-phenotype-in-knee-osteoarthritis-patients-using-machine-learning-npm/}}</ref> His concept of mitochondrial metabolic inflexibility as a primary cause of cartilage degradation has been influential. His proteomics research led to recognition by OARSI as the best researcher in 2017, contributing significantly to protein biomarkers and personalized medicine in osteoarthritis.

Moreover, Blanco pioneered cellular therapy with chondrocytes in Spain, implementing autologous chondrocyte implantation in his hospital and significantly influencing this therapy's clinical application in Spain.<ref>{{Cite journal |last=Piñeiro-Ramil |first=María |last2=Sanjurjo-Rodríguez |first2=Clara |last3=Rodríguez-Fernández |first3=Silvia |last4=Hermida-Gómez |first4=Tamara |last5=Blanco-García |first5=Francisco J. |last6=Fuentes-Boquete |first6=Isaac |last7=Vaamonde-García |first7=Carlos |last8=Díaz-Prado |first8=Silvia |date=2023-01-17 |title=Generation of human immortalized chondrocytes from osteoarthritic and healthy cartilage: a new tool for cartilage pathophysiology studies |url=https://boneandjoint.org.uk/Article/10.1302/2046-3758.121.BJR-2022-0207.R1 |journal=Bone & Joint Research |language=en |volume=12 |issue=1 |pages=46–57 |doi=10.1302/2046-3758.121.BJR-2022-0207.R1 |issn=2046-3758 |pmc=PMC9872042 |pmid=36647698}}</ref> As a result of his work in search of molecular biomarkers in rheumatic diseases and the creation of rheumatic disease cohorts as the PROCOAC, they have developed the Personalized Rheumatology Platform PR5P, which integrates several instruments to perform precision medicine (DIPROA, DITOBA, RESTOBA, OPTIBIO) for rheumatology patients.

==Awards==

* 2023 Honorary Title of Favorite Son of his hometown. Cee August 12th, 2023
* 2023 Recognition Award by the Rheumatology Spanish Society (SER). Sevilla, May 11th, 2023.
* 2019 European Awards in Medicine- Rheumatology. Paris, December 4th, 2019
* 2018 Clinical Research Award 2018, Syneos Health, North Caroline, USA.
* 2018 Award “XXI Century Medicine” in Rheumatology. Consejo Editorial de El Suplemento
* 2018 2018 “A Tu Salud” Prize in the area of Rheumatology, awarded by the news journal La Razón.
* 2018 Recognition Award by the Rheumatology Galician League.
* 2017 Osteoarthritis Research Society International (OARSI) Basic Science Award
* 2016 Special Jury Prize, ESPA (European Spa Association) Innovation Awards
* 2016 International Marcial Campos Prize on Thermal Research
* 2002, 2007 and 2017 Best Scientific Project Award, Royal Academic of Medicine and Surgery, A Coruña. Spain.
* 2001 Young Investigator Award, Galician Health Administration. Xunta de Galicia. Spain.


== References ==
== References ==
Line 11: Line 30:


==External links==
==External links==
*{{Google Scholar id|g2zTKEIAAAAJ}}
*{{Google Scholar id|iErXcnMAAAAJ}}

{{authority control}}

{{DEFAULTSORT:Blanco, Francisco J.}}
[[Category:Spanish medical researchers]]
[[Category:Living people]]
[[Category:Year of birth missing (living people)]]


{{Biologist-stub}}



{{authority control}}
{{authority control}}

Revision as of 14:05, 14 April 2024

Francisco Javier Blanco García,(Cee, A Coruña, 1963) is a Spanish-born medical professional, has established a notable career in the field of Rheumatology.[1] He is a Full Professor of Rheumatology at the University of A Coruña, Head of the Clinical and Translational Rheumatology Section at the A Coruña University Hospital, Coordinator of the Rheumatology-Health Research Group (GIR) at INIBIC and CICA-UDC, and Scientific Director of “Catedra UDC-FSR”.

Education

Francisco Javier Blanco García began his higher education at the Universidad de Santiago de Compostela, Spain, where he graduated with a Bachelor of Science degree in Medicine and Surgery in 1987, excelling as the First of Class. Blanco's postgraduate journey included a residency in Rheumatology at the Hospital Universitario 12 Octubre in Madrid, completed in 1992, and a Research Fellowship in Medicine at the University of California, San Diego, Martin Lot’s Lab in 1993-94. He achieved his PhD in Medicine from the Universidad de A Coruña, Spain, in 1998.[2][3]

Research

Prof. Francisco Javier Blanco García's research career is marked by pioneering contributions in rheumatology, particularly in understanding osteoarthritis.[4] He was the first to identify apoptosis in human joint chondrocytes, linking it to cartilage destruction in osteoarthritis and associating it with nitric oxide synthesis.[5] This revelation shifted the understanding of osteoarthritic cartilage destruction, previously attributed to necrosis.[6] Blanco is also a leader in studying mitochondria's role in osteoarthritis, notably in mitochondrial genetics as biomarkers for knee osteoarthritis.[7] His concept of mitochondrial metabolic inflexibility as a primary cause of cartilage degradation has been influential. His proteomics research led to recognition by OARSI as the best researcher in 2017, contributing significantly to protein biomarkers and personalized medicine in osteoarthritis.

Moreover, Blanco pioneered cellular therapy with chondrocytes in Spain, implementing autologous chondrocyte implantation in his hospital and significantly influencing this therapy's clinical application in Spain.[8] As a result of his work in search of molecular biomarkers in rheumatic diseases and the creation of rheumatic disease cohorts as the PROCOAC, they have developed the Personalized Rheumatology Platform PR5P, which integrates several instruments to perform precision medicine (DIPROA, DITOBA, RESTOBA, OPTIBIO) for rheumatology patients.

Awards

  • 2023 Honorary Title of Favorite Son of his hometown. Cee August 12th, 2023
  • 2023 Recognition Award by the Rheumatology Spanish Society (SER). Sevilla, May 11th, 2023.
  • 2019 European Awards in Medicine- Rheumatology. Paris, December 4th, 2019
  • 2018 Clinical Research Award 2018, Syneos Health, North Caroline, USA.
  • 2018 Award “XXI Century Medicine” in Rheumatology. Consejo Editorial de El Suplemento
  • 2018 2018 “A Tu Salud” Prize in the area of Rheumatology, awarded by the news journal La Razón.
  • 2018 Recognition Award by the Rheumatology Galician League.
  • 2017 Osteoarthritis Research Society International (OARSI) Basic Science Award
  • 2016 Special Jury Prize, ESPA (European Spa Association) Innovation Awards
  • 2016 International Marcial Campos Prize on Thermal Research
  • 2002, 2007 and 2017 Best Scientific Project Award, Royal Academic of Medicine and Surgery, A Coruña. Spain.
  • 2001 Young Investigator Award, Galician Health Administration. Xunta de Galicia. Spain.

References

  1. ^ "pdi.udc.es".
  2. ^ "Ilmo. Sr. D. Francisco Javier Blanco García - Real Academia Nacional de Medicina". www.ranm.es. Retrieved 2024-04-14.
  3. ^ "Dr. Francisco J. Blanco García". www.elsuplemento.es (in Spanish). Retrieved 2024-04-14.
  4. ^ jfersan2. "Reumatología". INIBIC (in Spanish). Retrieved 2024-04-14.{{cite web}}: CS1 maint: numeric names: authors list (link)
  5. ^ de Andrés, María C.; Maneiro, Emilia; Martín, Miguel A.; Arenas, Joaquín; Blanco, Francisco J. (2013-09-11). "Nitric oxide compounds have different effects profiles on human articular chondrocyte metabolism". Arthritis Research & Therapy. 15 (5): R115. doi:10.1186/ar4295. ISSN 1478-6354. PMC 3978712. PMID 24025112.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  6. ^ Caramés, Beatriz (2005). Implicación del factor de necrosis tumoral-alfa (TNF-alfa) y de interleuquina 1 (IL-1) en la disfunción mitocondrial del condrocito humano: estudio en el proceso apoptótico (http://purl.org/dc/dcmitype/Text thesis) (in Spanish). Universidade da Coruña. {{cite thesis}}: External link in |degree= (help)
  7. ^ "cica.udc.gal".
  8. ^ Piñeiro-Ramil, María; Sanjurjo-Rodríguez, Clara; Rodríguez-Fernández, Silvia; Hermida-Gómez, Tamara; Blanco-García, Francisco J.; Fuentes-Boquete, Isaac; Vaamonde-García, Carlos; Díaz-Prado, Silvia (2023-01-17). "Generation of human immortalized chondrocytes from osteoarthritic and healthy cartilage: a new tool for cartilage pathophysiology studies". Bone & Joint Research. 12 (1): 46–57. doi:10.1302/2046-3758.121.BJR-2022-0207.R1. ISSN 2046-3758. PMC 9872042. PMID 36647698.{{cite journal}}: CS1 maint: PMC format (link)

External links


Stub icon

This article about a biologist is a stub. You can help Wikipedia by expanding it.



Stub icon

This article about a biologist is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Francisco_J._Blanco&oldid=1218894361"